How should severe hypertension (blood pressure 230/110 mmHg) be managed in a patient with proliferative lupus nephritis (class III/IV) presenting with proteinuria, rising creatinine, polyserositis, and neuro‑psychiatric involvement?

Management of Severe Hypertension (BP 230/110) in Proliferative Lupus Nephritis with Multi-System Involvement

This patient requires immediate aggressive blood pressure control with renin-angiotensin system (RAS) blockade as the cornerstone antihypertensive agent, combined with urgent initiation of triple immunosuppressive therapy consisting of glucocorticoids (methylprednisolone pulses followed by oral prednisone), mycophenolic acid analogs (MPAA), and consideration of belimumab given the severe multi-system disease with neuropsychiatric involvement. 1

Immediate Blood Pressure Management

Target Blood Pressure

• Goal BP: <130/80 mmHg in this patient with lupus nephritis 1, 2
• The current BP of 230/110 mmHg represents severe hypertension requiring urgent but controlled reduction
• Avoid rapid BP reduction that could precipitate acute kidney injury or cerebrovascular events

First-Line Antihypertensive Strategy

RAS blockade (ACE inhibitors or ARBs) should be the foundation of antihypertensive therapy 1, 2:

• These agents provide dual benefit: BP control AND proteinuria reduction
• Safe and efficacious as first-choice treatment in lupus nephritis
• Essential for long-term renal protection and CKD progression prevention

Critical Caveat

• Avoid short-acting or IV antihypertensive medications for severe hypertension without acute target organ damage 3
• Rapid BP reduction is associated with adverse cardiovascular events and acute kidney injury
• Gradual BP reduction over days to weeks is preferred in the outpatient/non-emergency setting

Immunosuppressive Therapy for Class III/IV Lupus Nephritis

Initial Induction Regimen

Given the severity with neuropsychiatric involvement, polyserositis, and rising creatinine, recommend triple therapy 1:

1. Glucocorticoids - Start with methylprednisolone IV pulses:

   • 0.25-0.5 g/day for up to 3 days 1
   • Followed by oral prednisone using moderate-to-reduced dose scheme (0.5-0.7 mg/kg/day, max 50 mg) 1
   • Taper according to structured protocol over 6 months

2. Mycophenolic acid analogs (MPAA) 1:

   • Mycophenolate mofetil (MMF) 750-1000 mg twice daily, OR
   • Mycophenolic acid (MPA) 540-720 mg twice daily
   • This is the preferred backbone immunosuppressive agent

3. Belimumab - Strong consideration given:

   • Multi-system involvement (neuropsychiatric + polyserositis) 1, 4
   • Rising creatinine suggesting high risk for progression 1
   • Evidence shows belimumab + MPAA + glucocorticoids reduces flares and slows kidney function decline 4

Alternative Consideration

If nephrotic-range proteinuria is present, CNI-based triple therapy could be considered 1:

• Voclosporin, tacrolimus, or cyclosporine + MPAA + glucocorticoids
• Particularly effective for extensive podocyte injury
• However, belimumab-based regimen is preferred given the neuropsychiatric involvement and polyserositis 1

Addressing Multi-System Manifestations

Neuropsychiatric Involvement

• The severe hypertension itself may contribute to neuropsychiatric symptoms (consider posterior reversible encephalopathy syndrome - PRES) 5
• Aggressive BP control is critical to prevent/treat PRES
• Brain MRI should be obtained if not already done
• The immunosuppressive regimen above addresses both renal and neuropsychiatric lupus

Polyserositis

• Responds to systemic immunosuppression
• Monitor for cardiac tamponade (given polyserositis) 6
• May require pericardiocentesis if hemodynamically significant

Rising Creatinine

• Indicates active nephritis requiring aggressive immunosuppression
• Monitor closely for acute kidney injury
• May need renal replacement therapy if severe 5

Essential Adjunctive Measures

All patients with lupus nephritis should receive 1:

1. Hydroxychloroquine - Universal recommendation for all SLE patients
2. Proteinuria monitoring - Target reduction to <0.5 g/g within 6-12 months
3. Thrombosis prophylaxis - Assess for antiphospholipid antibodies given nephrotic-range proteinuria risk
4. Infection prevention - Given high-dose immunosuppression
5. Nephrotoxin avoidance - NSAIDs, contrast agents when possible

Common Pitfalls to Avoid

1. Do NOT use short-acting antihypertensives for severe BP without hypertensive emergency 3
2. Do NOT delay immunosuppression while waiting for BP control - these should be initiated simultaneously
3. Do NOT use cyclophosphamide as first-line in this patient - MPAA-based regimen preferred, and cyclophosphamide carries fertility risks 1
4. Do NOT undertreated the neuropsychiatric component - this requires the same aggressive immunosuppression as the nephritis 5, 7
5. Do NOT forget ABPM (ambulatory BP monitoring) - nocturnal hypertension is extremely common in lupus nephritis (84% have abnormal nocturnal dipping) and office BP alone is insufficient 8

Monitoring Strategy

• Weekly initially: BP, creatinine, proteinuria, clinical response
• Target response by 6-12 months: Proteinuria <0.5 g/g, stable/improved kidney function 1
• Total treatment duration: Minimum 36 months of combined immunosuppression 1
• Maintenance phase: Continue MPAA after initial therapy completion; if using belimumab or CNI, may continue triple therapy for extended period based on phase 3 trial data 1, 4